Webinar
Unlocking the Potential of Tricyclic Peptides – Antibody-Like Precision with Peptide Therapeutics
April 15, 2025 01:00 PM CET
Join us for an exclusive session on CLIPS™ multicycles, a novel class of constrained tricyclic peptides with enormous potential as next-generation peptide therapeutics. Explore how tricyclic peptides replicate key features of antibodies to achieve high-affinity and high-selectivity in target binding with greatly enhanced proteolytic stability as a bonus. Discover how our unique chemistry ensures single-isomer selection early in the screening process, combined with a high-diversity screening method. We will showcase the discovery and optimization of tricyclic peptides against high-value targets, like membrane receptor proteins and monoclonal antibodies. Whether you’re in research, biotech, or pharmaceuticals, learn how high-diversity tricyclic peptide screening might support your drug development projects.
Objectives:
- Get an in-depth view at a breakthrough peptide discovery platform
- Understand the competitive advantages of tricyclic peptides for drug development
- Learn from leading experts in the field of peptide drug discovery
Peter Timmerman
Peter Timmerman, Head of Peptide Science at Biosynth, joined the group following the acquisition of Pepscan in 2022, where he had served as chief scientific officer since 2001. He drives advancements in protein mimicry for peptide drug discovery programs. Timmerman is the inventor of CLIPS technology and previously held a chair as a Professor at the University of Amsterdam. He obtained his Chemistry degree from Vrije Universiteit (Amsterdam) and earned his PhD cum laude from the University of Twente. Timmerman has co-authored over 80 scientific papers and holds more than 10 patents.
Vito Thijssen
Dr. Vito Thijssen is a Senior Scientist in Biosynth’s Peptide Discovery & Mapping department. After completing his degree in Biomedical technology at University of Technology Eindhoven, he pursued a PhD in Chemical Biology and Drug Discovery at Utrecht University. During his PhD, he has worked on macrocyclic peptide discovery against viral fusion proteins using mRNA display technology. After his PhD he joined Biosynth’s Peptide discovery team to further work on peptide display technologies to aid drug discovery projects.